Pfizer (NYSE:PFE) recently ended its strategic collaboration with Acepodia and is facing legal challenges related to Depo-Provera, reflecting significant changes that provide a backdrop of strategic ...

Pfizer Inc. (NYSE:PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration ...

US Health Secretary Robert F. Kennedy Jr.'s decision to drop the Covid-19 vaccine from the CDC’s recommended immunization ...

Pfizer has abruptly ended its partnership with Acepodia, citing global resource shifts, not Acepodia’s competence. This split ...

Roivant Sciences Ltd. (($ROIV)) has held its Q4 earnings call. Read on for the main highlights of the call. Roivant Sciences Ltd. recently held ...

Oregon's ban on Project Veritas raises alarm bells for free speech advocates In a troubling development for free speech and whistleblower protection, various groups are rallying around Project Veritas ...

This summary of recent health news covers a U.S. government report error, China's ban on Brazilian poultry, legal action by ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Women Seek Justice Over Depo-Provera’s Alleged Risks** In a significant legal challenge, nearly 300 women have filed lawsuits against Pfizer ...

A summary of current health news includes topics such as the Trump administration's inaccurate health report, China's ban on ...

Pfizer Vietnam, in collaboration with the Vietnam Association of Preventive Medicine, organised on June 3 and June 5 a series ...

Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's sweeping executive order to slash prescription drug prices would be difficult to ...